```html

Nasal Melanoma – A Complete Patient‑Friendly Guide

Overview

Nasal melanoma is a rare type of malignant melanoma that originates in the mucosal lining of the nose and paranasal sinuses. Unlike the more common cutaneous melanoma, which arises from skin exposed to sunlight, nasal melanoma develops on the moist, sun‑protected mucosa inside the nasal cavity.

Who it affects: It can occur at any age but most cases are diagnosed in adults between 50‑70 years. Men are slightly more likely than women (approximately 1.3 : 1 ratio). While the overall incidence is low, it represents about 1‑2 % of all melanomas and 5‑8 % of all head‑and‑neck melanomas.<sup>1</sup>

Prevalence: In the United States, an estimated 1,000‑1,200 new cases of mucosal melanoma (including nasal) are diagnosed each year, with nasal melanoma accounting for roughly 150‑200 of those cases.<sup>2</sup> Because of its rarity, many physicians are unfamiliar with it, which can delay diagnosis.

Symptoms

Symptoms are often vague and develop slowly, which is why they are frequently mistaken for sinus infections or allergies. Below is a complete list of reported manifestations, along with brief descriptions.

• Nasal obstruction or congestion – Persistent feeling of a “blocked” nose that does not improve with decongestants.
• Epistaxis (nosebleeds) – Frequent, unilateral bleeding that may be bright red or dark (indicative of tumor vascularity).
• Unilateral nasal discharge – May be watery, mucoid, or blood‑streaked.
• Change in nasal shape or visible mass – A dark, pigmented lesion may be seen on anterior rhinoscopy; sometimes the mass is non‑pigmented.
• Pain or pressure – Dull facial pain, especially over the cheekbones or forehead, that worsens over weeks.
• Loss of sense of smell (anosmia) or reduced smell (hyposmia).
• Ear fullness or hearing loss – Tumor can extend into the eustachian tube, causing middle‑ear effusion.
• Dental or tooth‑root pain – Invasion into the maxillary sinus may affect the upper teeth.
• Facial swelling or asymmetry – Advanced disease can cause soft‑tissue swelling.
• Headache – Particularly if the tumor invades the skull base.
• Weight loss, fatigue, night sweats – Systemic “B symptoms” may appear in advanced disease.

Causes and Risk Factors

The exact cause of nasal melanoma is not fully understood, but several factors appear to increase risk.

Genetic and Molecular Factors

• Mutations in the KIT gene – Found in 15‑20 % of mucosal melanomas and can drive tumor growth.
• NRAS and BRAF mutations – Less common than in cutaneous melanoma but still present in a minority of cases.
• Chromosomal aberrations – Gains in chromosome 1q and losses in 6q have been reported.

Environmental & Lifestyle Factors

• Chronic irritation – Long‑standing inflammatory conditions (e.g., allergic rhinitis, chronic sinusitis) may create a micro‑environment that facilitates malignant transformation.
• Occupational exposure – Rare reports link exposure to wood dust, asbestos, or certain chemicals (e.g., formaldehyde) with mucosal melanoma.
• Smoking – While not a direct cause, smoking is associated with increased risk of sinonasal malignancies overall.

Demographic Factors

• Age – Incidence rises sharply after age 50.
• Sex – Slight male predominance.
• Race – Higher rates in Caucasians, likely reflecting overall melanoma epidemiology.

Diagnosis

Early diagnosis hinges on a high index of suspicion. The work‑up typically follows these steps:

1. Clinical Examination

• Detailed otolaryngologic (ENT) exam with nasal endoscopy to visualize the lesion.
• Documentation of size, color, ulceration, and mobility.

2. Biopsy

A tissue sample is essential. Options include:

• Endoscopic forceps biopsy – Most common; performed under local anesthesia.
• Incisional or excisional biopsy – May be needed for larger lesions.
• Specimens are sent for histopathology and immunohistochemical staining (S100, HMB‑45, Melan‑A) to confirm melanoma.

3. Imaging Studies

• Contrast‑enhanced CT scan – Defines bony erosion, sinus involvement, and surgical planning.
• MRI with gadolinium – Superior for soft‑tissue, perineural spread, and skull‑base invasion.
• PET‑CT – Stages disease by detecting regional lymph nodes and distant metastases.

4. Staging

The American Joint Committee on Cancer (AJCC) 8th edition staging system for mucosal melanoma is used. It incorporates tumor (T) size and extent, nodal (N) involvement, and distant metastasis (M). Most patients present at stage III or IV.

5. Molecular Testing

Testing for KIT, BRAF, and NRAS mutations guides targeted therapy decisions. This is usually performed on the same biopsy specimen.

Treatment Options

Treatment is multimodal and highly individualized based on stage, tumor location, molecular profile, and patient health.

1. Surgery

• Endoscopic endonasal resection – Minimally invasive; preferred for early‑stage tumors confined to the nasal cavity.
• Open craniofacial resection – Required for extensive disease involving the orbit, skull base, or paranasal sinuses.
• Goal: achieve negative margins (R0 resection). Unfortunately, clear margins are difficult; recurrence rates are high (40‑60 %).

2. Radiation Therapy

• External beam radiation (EBRT) – Often used post‑operatively or as definitive therapy when surgery is not feasible.
• Intensity‑modulated radiation therapy (IMRT) or proton therapy – Allows higher doses while sparing critical structures.
• Typical dose: 60‑70 Gy in 2 Gy fractions.

3. Systemic Therapy

• Immunotherapy
  • Checkpoint inhibitors: nivolumab (PD‑1) or pembrolizumab alone, or in combination with ipilimumab (CTLA‑4). These agents have shown overall response rates of 20‑30 % in mucosal melanoma, albeit lower than cutaneous melanoma.
• Targeted therapy
  • For KIT‑mutated tumors: imatinib or newer KIT inhibitors (e.g., nilotinib, dasatinib). Response rates around 15‑25 %.
• Chemotherapy – Historically used (e.g., dacarbazine) but offers limited benefit; now largely superseded by immunotherapy.

4. Clinical Trials

Enrollment in trials investigating novel agents (e.g., bispecific antibodies, combination immunotherapy, adoptive T‑cell therapy) is encouraged, especially for advanced disease.

5. Supportive & Lifestyle Measures

• Smoking cessation.
• Optimization of nutrition to maintain weight.
• Regular dental and ENT follow‑up to monitor for recurrence.

Living with Nasal Melanoma

Survivorship care focuses on managing treatment side effects, monitoring for recurrence, and maintaining quality of life.

Daily Management Tips

• Nasal hygiene – Saline rinses (e.g., Neti pot) can keep the nasal passages moist and reduce crusting after surgery or radiation.
• Skin protection – Even though the tumor is mucosal, patients with melanoma are at higher risk for cutaneous lesions; use sunscreen and perform regular skin checks.
• Manage fatigue – Pace activities, schedule short naps, and stay hydrated.
• Address taste and smell changes – Use herbs and strong flavors; consider a referral to a speech‑language pathologist.
• Emotional health – Join support groups (e.g., Melanoma Support Network) and consider counseling.
• Follow‑up schedule – Typically every 3 months for the first 2 years, then every 6 months up to 5 years, and annually thereafter. Each visit includes endoscopic exam, imaging as indicated, and labs.

Prevention

Because nasal melanoma arises in protected mucosa, primary prevention is challenging. However, some measures can lower overall melanoma risk.

• Quit smoking and avoid exposure to occupational irritants.
• Control chronic sinus inflammation with appropriate medical therapy (e.g., intranasal corticosteroids).
• Promptly treat persistent unilateral nasal symptoms; do not assume they are “just allergies.”
• Maintain a healthy immune system: balanced diet, regular exercise, adequate sleep.
• If you have a known KIT or other melanoma‑related mutation, discuss surveillance plans with your oncologist.

Complications

If left untreated or if treatment fails, several serious complications can arise:

• Local invasion – Destruction of the nasal septum, orbit, or skull base, leading to visual loss, facial deformity, or cerebrospinal fluid leak.
• Regional lymph node metastasis – Most commonly to the cervical nodes, requiring neck dissection.
• Distant metastasis – Liver, lungs, brain, and bone are common sites; median overall survival for metastatic nasal melanoma is 12‑18 months.
• Chronic sinusitis and obstruction – May necessitate repeat surgeries.
• Radiation‑induced toxicity – Xerostomia, osteoradionecrosis of the facial bones, or mucosal ulceration.
• Psychological impact – Depression and anxiety are reported in up to 30 % of patients.

When to Seek Emergency Care

---

Sources:
1. Mayo Clinic. “Mucosal melanoma.” Accessed 2024.
2. National Cancer Institute (NCI). “Rare Cancers: Mucosal Melanoma.” 2023.
3. American Academy of Otolaryngology–Head and Neck Surgery. Clinical Practice Guidelines for Sinonasal Malignancies, 2022.
4. WHO Classification of Head and Neck Tumours, 5th Edition, 2022.
5. J. T. Stransky et al., “Molecular landscape of mucosal melanoma,” Nature Genetics, 2021.

```